CORE--Molecular Resources Core
CORE--分子资源核心
基本信息
- 批准号:7312504
- 负责人:
- 金额:$ 27.47万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-03-01 至 2010-02-28
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Core C, the Molecular Resources Core, will provide molecular reagents and services to all four projects and will be crucial to the completion of the specific aims of each proposal in the Program Project. The proposal for a Molecular Resources Core is a continuation of the original Core C. The overall function of Core C is to provide molecular reagents and expertise, including generation of deletion and site-directed mutants and incorporation into the desired expression vectors, creation of minigene constructs, generation of adenoviral and retroviral constructs for transduction of primary endothelial cells and designing and generating appropriate siRNA based constructs. This core will be directed by Dr. Randal A. Skidgel and will be staffed by a full-time Senior Research Specialist (Dr. Barbara Keith), full- time Research Specialist (TBN) and part-time Research Associate (Vidas Dumasias). Consolidating these efforts in Core C will result in increased speed and efficiency in accomplishing the research tasks outlined in each of the
projects and uniformity of approaches and methods so that resutts from each project can be compared. In addition, it will allow strict quality control and consistency of molecular reagents to be used by the various projects. Furthermore, an added and important benefit of the centralized Core C will be to markedly decrease expenses compared to a scenario in which each project would generate its own molecular resources. Regular meetings of the Core leader with the Senior Research Specialist and project leaders will assure coordination and prioritization of the generation of molecular reagents and assure that the desired reagents are provided in a timely manner to the component projects.
Core C是分子资源核心,将为所有四个项目提供分子试剂和服务,这对于计划项目中每个提案的具体目标至关重要。分子资源核心的建议是延续原始核心C。核心C的总体功能是提供分子试剂和专业知识,包括产生删除和定位的突变体,并将其纳入所需的表达载体,创建微型型构建体,腺病毒的产生和逆转录病毒构造,以构建原始的原始型细胞和依次构造和构造的原始代理和设计。该核心将由Randal A. Skidgel博士执导,并将由专职高级研究专家(Barbara Keith博士),全职研究专家(TBN)和兼职研究助理(Vidas Dumasias)组成。在核心C中巩固这些努力将提高速度和效率,以完成每一个中概述的研究任务
可以比较每个项目中的项目和方法的统一性,以便可以比较每个项目的重新打击。此外,这将允许各种项目使用的严格质量控制和分子试剂的一致性。此外,与每个项目产生自己的分子资源相比,集中式核心C的附加和重要好处是显着降低支出。核心领导者与高级研究专家和项目负责人的定期会议将确保分子试剂产生的协调和优先级,并确保及时向组件项目提供所需的试剂。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Randal A Skidgel其他文献
Randal A Skidgel的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Randal A Skidgel', 18)}}的其他基金
Developing a new drug for treating myocardial ischemia/reperfusion injury
开发治疗心肌缺血/再灌注损伤的新药
- 批准号:
10491205 - 财政年份:2021
- 资助金额:
$ 27.47万 - 项目类别:
Developing a new drug for treating myocardial ischemia/reperfusion injury
开发治疗心肌缺血/再灌注损伤的新药
- 批准号:
10325868 - 财政年份:2021
- 资助金额:
$ 27.47万 - 项目类别:
Targeting integrin outside-in signaling for treating sepsis
靶向整合素由外向内信号传导治疗脓毒症
- 批准号:
10461718 - 财政年份:2018
- 资助金额:
$ 27.47万 - 项目类别:
Targeting integrin outside-in signaling for treating sepsis
靶向整合素由外向内信号传导治疗脓毒症
- 批准号:
10625353 - 财政年份:2018
- 资助金额:
$ 27.47万 - 项目类别:
Post-translational Regulation of High Output NO and Endothelial Barrier Dysfuncti
高输出 NO 和内皮屏障功能障碍的翻译后调节
- 批准号:
8059128 - 财政年份:2011
- 资助金额:
$ 27.47万 - 项目类别:
Post-Translational Regulation of High Output NO and Endothelial Barrier Dysfuncti
高输出 NO 和内皮屏障功能障碍的翻译后调节
- 批准号:
7367821 - 财政年份:2007
- 资助金额:
$ 27.47万 - 项目类别:
Post-Translational Regulation of High Output NO and Endothelial Barrier Dysfuncti
高输出 NO 和内皮屏障功能障碍的翻译后调节
- 批准号:
7312500 - 财政年份:2006
- 资助金额:
$ 27.47万 - 项目类别:
Post-Translational Regulation of High Output NO and Endothelial Barrier Dysfuncti
高输出 NO 和内皮屏障功能障碍的翻译后调节
- 批准号:
6967980 - 财政年份:2005
- 资助金额:
$ 27.47万 - 项目类别:
相似海外基金
Microfluidic Devices for High Throughput Gene Synthesis
用于高通量基因合成的微流控装置
- 批准号:
7386921 - 财政年份:2008
- 资助金额:
$ 27.47万 - 项目类别: